The potential for commonly used anesthetics and sedatives to cause neuroapoptosis and other neurodegenerative changes in the developing mammalian brain has become evident in animal studies over the past 15 years. This concern has led to a number of retrospective studies in human infants and young children, and some of these studies observed an association between exposure to general anesthesia as an infant, and later neurobehavioral problems in childhood. This association is particularly evident for prolonged or repeated exposures. Because of the significant growth of fetal interventions requiring sedation and analgesia for the fetus, or because of maternal anesthetic effects, this concern about anesthetic neurotoxicity is relevant for the fetus. The potential for anesthetic neurotoxicity is the most important clinical and research problem in the field of pediatric anesthesiology. This review will first briefly summarize the rapid brain growth and development in the fetus and neonate. Next, animal model data of anesthetic neurotoxicity in the fetus and neonate will be presented, followed by a review of recent human clinical anesthetic neurotoxicity trials. Finally, the rationale for studying dexmedetomidine as a potential neuroprotectant agent in anesthetic neurotoxicity will be reviewed along with study design for two human clinical trials involving dexmedetomidine.

Keywords:
Anesthetic neurotoxicity, Neonate, Fetus, Dexmedetomidine, Isoflurane, Sevoflurane
1.
Rappaport BA, Suresh S, Hertz S, Evers AS, Orser BA: Anesthetic neurotoxicity - clinical implications of animal models. N Engl J Med 2015;372:796-797.
2.
Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vöckler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW: Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999;283:70-74.
3.
Jevtovic-Todorovic V, Hartman RE, Izumi Y, Benshoff ND, Dikranian K, Zorumski CF, Olney JW, Wozniak DF: Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci 2003;23:876-882.
4.
Paule MG, Li M, Allen RR, Liu F, Zou X, Hotchkiss C, Hanig JP, Patterson TA, Slikker W Jr, Wang C: Ketamine anesthesia during the first week of life can cause long-lasting cognitive deficits in rhesus monkeys. Neurotoxicol Teratol 2011;33:220-230.
5.
Creeley CE, Dikranian KT, Dissen GA, Back SA, Olney JW, Brambrink AM: Isoflurane-induced apoptosis of neurons and oligodendrocytes in the fetal rhesus macaque brain. Anesthesiology 2014;120:626-638.
6.
Wilder RT, Flick RP, Sprung J, Katusic SK, Barbaresi WJ, Mickelson C, Gleich SJ, Schroeder DR, Weaver AL, Warner DO: Early exposure to anesthesia and learning disabilities in a population-based birth cohort. Anesthesiology 2009;110:796-804.
7.
DiMaggio C, Sun LS, Ing C, Li G: Pediatric anesthesia and neurodevelopmental impairments: a Bayesian meta-analysis. J Neurosurg Anesthesiol 2012;24:376-381.
8.
Psaty BM, Platt R, Altman RB: Neurotoxicity of generic anesthesia agents in infants and children: an orphan research question in search of a sponsor. JAMA 2015;313:1515-1516.
9.
Lin EP, Soriano SG, Loepke AW: Anesthetic neurotoxicity. Anesthesiol Clin 2014;32:133-155.
10.
Olsen EA, Brambrink AM: Anesthetic neurotoxicity in the newborn and infant. Curr Opin Anaesthesiol 2013;26:535-542.
11.
Davidson A, Flick RP: Neurodevelopmental implications of the use of sedation and analgesia in neonates. Clin Perinatol 2013;40:559-573.
12.
Davidson AJ, Becke K, de Graaff J, Giribaldi G, Habre W, Hansen T, Hunt RW, Ing C, Loepke A, McCann ME, Ormond GD, Pini Prato A, Salvo I, Sun L, Vutskits L, Walker S, Disma N: Anesthesia and the developing brain: a way forward for clinical research. Paediatr Anaesth 2015;25:447-452.
13.
Tymofiyeva O, Hess CP, Xu D, Barkovich AJ: Structural MRI connectome in development: challenges of the changing brain. Br J Radiol 2014;87:20140086.
14.
Huang H, Vasung L: Gaining insight of fetal brain development with diffusion MRI and histology. Int J Dev Neurosci 2014;32:11-22.
15.
Sanders RD, Hassell J, Davidson AJ, Robertson NJ, Ma D: Impact of anaesthetics and surgery on neurodevelopment: an update. Br J Anaesth 2013;110(suppl 1):i53-i72.
16.
Istaphanous GK, Ward CG, Nan X, Hughes EA, McCann JC, McAuliffe JJ, Danzer SC, Loepke AW: Characterization and quantification of isoflurane-induced developmental apoptotic cell death in mouse cerebral cortex. Anesth Analg 2013;116:845-854.
17.
Istaphanous GK, Ward CG, Loepke AW: The impact of the perioperative period on neurocognitive development, with a focus on pharmacological concerns. Best Pract Res Clin Anaesthesiol 2010;24:433-449.
18.
Coleman K, Robertson ND, Dissen GA, Neuringer MD, Martin LD, Carlson VC, Kroenke C, Fair D, Brambrink AM: Isoflurane anesthesia has long-term consequences on motor and behavioral development in infant rhesus macaques. Anesthesiology 2017;126:74-84.
19.
Li J, Xiong M, Nadavaluru PR, Zuo W, Ye JH, Eloy JD, Bekker A: Dexmedetomidine attenuates neurotoxicity induced by prenatal propofol exposure. J Neurosurg Anesthesiol 2016;28:51-64.
20.
Duan X, Li Y, Zhou C, Huang L, Dong Z: Dexmedetomidine provides neuroprotection: impact on ketamine-induced neuroapoptosis in the developing rat brain. Acta Anaesthesiol Scand 2014;58:1121-1126.
21.
Koo E, Oshodi T, Meschter C, Ebrahimnejad A, Dong G: Neurotoxic effects of dexmedetomidine in fetal cynomolgus monkey brains. J Toxicol Sci 2014;39:251-262.
22.
Olutoye OA, Lazar DA, Akinkuotu AC, Adesina A, Olutoye OO: Potential of the ovine brain as a model for anesthesia-induced neuroapoptosis. Pediatr Surg Int 2015;31:865-869.
23.
Sun L: Early childhood general anaesthesia exposure and neurocognitive development. Br J Anaesth 2010;105(suppl 1):i61-i68.
24.
North American Fetal Therapy Network. https://www.naftnet.org/.
25.
Rollins MD, Rosen MA: Anesthesia for fetal intervention and surgery; in Gregory GA, Andropoulos DB (eds): Pediatric Anesthesia, ed 5. Oxford, Wiley-Blackwell, 2012, pp 444-474.
26.
Hansen TG, Pedersen JK, Henneberg SW, Pedersen DA, Murray JC, Morton NS, Christensen K: Academic performance in adolescence after inguinal hernia repair in infancy: a nationwide cohort study. Anesthesiology 2011;114:1076-1085.
27.
Ing C, DiMaggio C, Whitehouse A, Hegarty MK, Brady J, von Ungern-Sternberg BS, Davidson A, Wood AJ, Li G, Sun LS: Long-term differences in language and cognitive function after childhood exposure to anesthesia. Pediatrics 2012;130:e476-e485.
28.
Stratmann G, Lee J, Sall JW, Lee BH, Alvi RS, Shih J, Rowe AM, Ramage TM, Chang FL, Alexander TG, Lempert DK, Lin N, Siu KH, Elphick SA, Wong A, Schnair CI, Vu AF, Chan JT, Zai H, Wong MK, Anthony AM, Barbour KC, Ben-Tzur D, Kazarian NE, Lee JY, Shen JR, Liu E, Behniwal GS, Lammers CR, Quinones Z, Aggarwal A, Cedars E, Yonelinas AP, Ghetti S: Effect of general anesthesia in infancy on long-term recognition memory in humans and rats. Neuropsychopharmacology 2014;39:2275-2287.
29.
Davidson AJ, Disma N, de Graaff JC, Withington DE, Dorris L, Bell G, Stargatt R, Bellinger DC, Schuster T, Arnup SJ, Hardy P, Hunt RW, Takagi MJ, Giribaldi G, Hartmann PL, Salvo I, Morton NS, von Ungern Sternberg BS, Locatelli BG, Wilton N, Lynn A, Thomas JJ, Polaner D, Bagshaw O, Szmuk P, Absalom AR, Frawley G, Berde C, Ormond GD, Marmor J, McCann ME; GAS consortium: Neurodevelopmental outcome at 2 years of age after general anaesthesia and awake-regional anaesthesia in infancy (GAS): an international multicentre, randomised controlled trial. Lancet 2016;387:239-250.
30.
Sun LS, Li G, Miller TL, Salorio C, Byrne MW, Bellinger DC, Ing C, Park R, Radcliffe J, Hays SR, DiMaggio CJ, Cooper TJ, Rauh V, Maxwell LG, Youn A, McGowan FX: Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood. JAMA 2016;315:2312-2320.
31.
Su F, Nicolson SC, Gastonguay MR, Barrett JS, Adamson PC, Kang DS, Godinez RI, Zuppa AF: Population pharmacokinetics of dexmedetomidine in infants after open heart surgery. Anesth Analg 2010;110:1383-1392.
32.
Precedex™ Prescribing Information. https://www.hospira.com/en/images/EN-4271_tcm81-92504.pdf.
33.
Mahmoud M, Mason KP: Dexmedetomidine: review, update, and future considerations of paediatric perioperative and periprocedural applications and limitations. Br J Anaesth 2015;115:171-182.
34.
Chrysostomou C, Sanchez-de-Toledo J, Wearden P, Jooste EH, Lichtenstein SE, Callahan PM, Suresh T, O'Malley E, Shiderly D, Haney J, Yoshida M, Orr R, Munoz R, Morell VO: Perioperative use of dexmedetomidine is associated with decreased incidence of ventricular and supraventricular tachyarrhythmias after congenital cardiac operations. Ann Thorac Surg 2011;92:964-972.
35.
Sanders RD, Xu J, Shu Y, Januszewski A, Halder S, Fidalgo A, Sun P, Hossain M, Ma D, Maze M: Dexmedetomidine attenuates isoflurane-induced neurocognitive impairment in neonatal rats. Anesthesiology 2009;110:1077-1085.
36.
Sanders RD, Sun P, Patel S, Li M, Maze M, Ma D: Dexmedetomidine provides cortical neuroprotection: impact on anaesthetic-induced neuroapoptosis in the rat developing brain. Acta Anaesthesiol Scand 2010;54:710-716.
37.
Liao Z, Cao D, Han X, Liu C, Peng J, Zuo Z, Wang F, Li Y: Both JNK and P38 MAPK pathways participate in the protection by dexmedetomidine against isoflurane-induced neuroapoptosis in the hippocampus of neonatal rats. Brain Res Bull 2014;107:69-78.
38.
Li Y, Zeng M, Chen W, Liu C, Wnag F, Han F, Zuo Z, Peng S: Dexmedetomidine reduces isoflurane-induced neuroapoptosis partly by preserving PI3K/Akt pathway in the hippocampus of neonatal rats. PLoS One 2014; e93639.
39.
Liu JR, Yuki K, Baek C, Han XH, Soriano SG: Dexmedetomidine-induced neuroapoptosis is dependent on its cumulative dose. Anesth Analg 2016;123:1008-1017.
40.
Pancaro C, Segal BS, Sikes RW, Almeer Z, Schumann R, Azocar RJ, Marchand JE: Dexmedetomidine and ketamine show distinct patterns of cell degeneration and apoptosis in the developing rat neonatal brain. J Matern Fetal Neonatal Med 2016;29:3827-3833.
41.
The T REX pilot study: a study to investigate the use of an alternative anaesthetic in infants. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02353182?term=TREX&rank=4; NCT02353182.
42.
Tourrel F, de Lendeu PK, Abily-Donval L, Chollat C, Marret S, Dufrasne F, Compagnon P, Ramdani Y, Dureuil B, Laudenbach V, Gonzalez BJ, Jégou S: The antiapoptotic effect of remifentanil on the immature mouse brain: an ex vivo study. Anesth Analg 2014;118:1041-1051.
43.
A phase I study of dexmedetomidine bolus and infusion in corrective infant cardiac surgery: safety and pharmacokinetics. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01915277?term=andropoulos&rank=2; NCT01915277.
44.
US Food and Drug Administration Website: http://www.fda.gov/Drugs/DrugSafety/ucm532356.htm; accessed December 23, 2016.
45.
Andropoulos DB, Greene MF: Anesthesia and developing brains: implications of the FDA warning. N Engl J Med 2017;376:905-907.
46.
Boney O, Bell M, Bell N, Conquest A, Cumbers M, Drake S, Galsworthy M, Gath J, Grocott MP, Harris E, Howell S, Ingold A, Nathanson MH, Pinkney T, Metcalf L: Identifying research priorities in anaesthesia and perioperative care: final report of the joint National Institute of Academic Anaesthesia/James Lind Alliance Research Priority Setting Partnership. BMJ Open 2015;5:e010006.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.